2017 EUnetHTA Assembly and Forum Video and Quality Survey
2017 EUnetHTA Assembly and Forum Video and Quality Survey Have a few minutes? We would like to invite all participants to complete a quality survey so we can only get better: Click here to evaluate the EUnetHTA Assembly Click here to evaluate the EUnetHTA Forum
Building. Progress. Advancement: The 2017 EUnetHTA Assembly and Forum a Success
Forum presentations attached The 2017 EUnetHTA Assembly and Forum, Amsterdam, the Netherlands has concluded. Immeasurable thanks to all participants and speakers, who took time out of busy schedules and risked high winds to arrive in Amsterdam. We know our mission is a partnership with some of the most dedicated and talented people Europe has to […]
EUnetHTA Magazine – Fall 2017
Interview with Commissioner Andriukaitis, Partner Profiles: Lithuania, Impact: Hungary and Finland, EMA: Parallel Consultations EUnetHTA Magazine, Fall 2017
The EUnetHTA JA3 2017 Assembly and Forum Welcome Pack (with Forum Agenda) and How to Get Around Amsterdam
Welcome to the 2017 Assembly and Forum; Amsterdam, The Netherlands 2017 Assembly and Forum Welcome Pack (with Forum Agenda) How to get Around Amsterdam 2017_welcome_pack3
An Invitation to the September 14, 2017 EUnetHTA Forum
Hotel NH Amsterdam Schiphol Airport 495 Kruisweg 2132 NA Amsterdam (Hoofddorp), The Netherlands Attend the 2017 EUnetHTA Forum (Thursday, September 14) entitled “Building. Progress. Advancement.” to be held in Amsterdam, the Netherlands. The EUnetHTA Forum provides a framework for updates and decisions relevant to the Consortium and a platform for networking, regular network-wide scientific discussions […]
Statement for Meeting with Heads of Agencies/High level representatives, 13.6.2017
Heads of Agencies (or agencies with HTA responsibility), from Countries included in EUnetHTA Executive Board (morning session) On June 13, 2017, in a meeting facilitated by the EUnetHTA Directorate and supported by DG SANTE, Heads of HTA Agencies from Countries represented in EUnetHTA JA3 Executive Board came together to discuss opportunities of closer collaboration in […]
Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Final project plan for pharma JA Regorafenib (Stivarga©) This is the final project plan of the pharma JA on Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatment. Project Plan
Meeting with Heads of Agencies/High-Level Representatives and Heads of European Pharmaceutical Companies
On 13 June, in a meeting facilitated by the EUnetHTA Directorate and supported by DG SANTE, European stakeholders of Health Technology Assessments (focus pharmaceuticals) came together to discuss important new developments for further cooperation. The EUnetHTA Directorate and DG SANTE specifically welcomed the participation and strong commitment of high-level representatives of HTA agencies[1] representing the […]
Press Release: EMA and EUnetHTA step up interaction to align data requirements
A new joint platform for parallel consultation will provide advice to medicine developers and facilitate access to medicines for patients The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) are stepping up their efforts to provide developers of medicines with simultaneous, coordinated advice on their development plans and facilitate alignment […]
WP4 OTCA02 on “Antibacterial-coated Sutures Versus Non-Antibacterial-Coated Sutures for the Prevention of Abdominal, Superficial and Deep Incisional, Surgical Site Infection (SSI)” is now available.
We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL AND DEEP INCISIONAL, SURGICAL SITE INFECTION (SSI)” is available. Surgical site infection (SSI) is a frequent type of nosocomial infection, accounting for about 14% to 15% of the total number […]
